A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06829797 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER_GOV

Sponsor class

Conditions

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Neoadjuvant Therapy(QL1706+SOX Chemotherapy)
DRUG: Neoadjuvant Therapy(SOX Chemotherapy)
PROCEDURE: Radical surgery (D2)
DRUG: Drug: Adjuvant therapy(QL1706+SOX chemotherapy)
DRUG: Drug: Adjuvant therapy(SOX chemotherapy)

Sponsor

Shandong Provincial Hospital